Results showed that siglec1, CD22 (i.e. siglec2), CD33 (i.e. siglec3), siglec5, siglec7, siglec9, siglec10, siglec11, siglec14, siglec15 and siglec16 were significantly up-regulated in AML patients, whereas MAG (i.e. siglec4), siglec6 and siglec8 were significantly down-regulated in AML patients. Here, CD22 is linked to acute myeloid leukemia.